Recent Updates
Recently added Catalysts
GANX Positive Sentiment

Unified Parkinson’s Disease Rating Scale (UPDRS) Explained

Key Takeaway: The Unified Parkinson’s Disease Rating Scale (UPDRS) is a key tool for assessing Parkinson's disease severity, covering motor and non-motor functions. It includes four parts, with the recent MDS-UPDRS update enhancing its effectiveness. The scale is widely used in clinical practice and research to monitor symptom progression and evaluate treatment efficacy.
Price reaction · baseline $2.38 (2025-03-18 close) · hit after-hours · clean, no other GANX news in the window
day 0 close · peak
+3.8%

Market Sentiment Analysis

POSITIVE FACTORS

  • UPDRS is a gold standard for monitoring Parkinson's symptoms.
  • It provides a comprehensive assessment of both motor and non-motor functions.
  • The updated MDS-UPDRS improves clarity and organization of the evaluation.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+62%
120-day peak, hindsight
Typical move
7.1%
average across 11 past catalysts
Cash runway
~8 mo
High dilution risk
Lead asset
Low Dose GT-02287
Phase 2 · Parkinson Disease

Full Press Release Details

What is the UPDRS?

The Unified Parkinson’s Disease Rating Scale, or UPDRS, is an assessment tool designed to assist clinicians and researchers in evaluating the severity of Parkinson’s disease a patient is suffering from. It assesses many aspects of motor function, as well as non-motor functions such as cognitive function, mental state, and overall daily living.
There are four parts of the UPDRS. Part 1 assesses mentation, behavior, and mood; part 2 covers activities of daily living; part 3 is a motor examination, and part 4 evaluates complications of therapy. Parts 1-3 are scored on a numerical scale, whereas part 4 is scored on a dichotomous scale using yes/no answers. In total, the 50-question evaluation regularly takes about half an hour and is completed with a physician alongside the patient.
Learn more: Medicine That Matters: An Interview with Jonas Hannestad, MD, PhD – Chief Medical Officer

Utilization of UPDRS in clinical practice and research

The UPDRS is a clinical ‘gold standard’ for monitoring symptom development in Parkinson’s patients. It is a useful tool for identifying symptom onset, as well as symptom progression throughout the patient’s lifetime. The ability to objectively monitor symptom fluctuation also makes it a very useful tool in Parkinson’s research. Neurologists use the UPDRS during clinical trials to evaluate the efficacy of a medication or therapeutic at stalling or reducing symptom progression. The UPDRS can be used in a variety of settings, including inpatient, outpatient, and as part of in-home healthcare regimens.
Learn more: Gain Therapeutics Reports Positive Results from Single Ascending Dose (SAD) Part of Phase 1 Clinical Trial of GT-02287 for GBA1 Parkinson’s Disease

MDS-UPDRS: recent updates to the UPDRS by the Movement Disorder Society

The UPDRS was originally developed in the 1980s but underwent a more recent update in 2008 by the Movement Disorder Society. This updated version (the MDS-UPDRS) addresses areas of concern from the original UPDRS, including reading comprehension, scoring scales, and organization of the exam.
The original UPDRS utilized a combination of numerical and dichotomous scoring scales, which were updated to a consistent numerical scale for all questions. A great amount of reorganization went into updated evaluation, particularly separating non-motor and motor function evaluations into different sections. In addition, the evaluation was updated to increase emphasis on slight deficits in addition to severe disabilities. There are still four parts to the updated MDS-UPDRS, but they are organized differently. Part 1 evaluates non-motor experiences of daily living; part 2 covers motor experiences of daily living; part 3 is still the motor examination; and part 4 assesses motor complications.

Frequently Asked Questions

What does the UPDRS assess?

The UPDRS evaluates the severity of Parkinson's disease, covering motor and non-motor functions.

How is the UPDRS structured?

The UPDRS consists of four parts assessing mentation, daily living activities, motor examination, and therapy complications.

What is the significance of the MDS-UPDRS?

The MDS-UPDRS updates the original scale for better clarity and organization in assessing Parkinson's symptoms.

How long does it take to complete the UPDRS?

The UPDRS evaluation typically takes about half an hour to complete with a physician.

Last updated: Mar 19, 2025